Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced ...

Bristol-Myers Squibb: Increased Global Breyanzi Sales Isn't Only Hematological Product Growth

BMY's growth-driving portfolio increased 17% year-over-year, prompting an upward revision in 2025 revenue guidance and ...

How a humble weed became a superstar of biology

Arabidopsis thaliana was always an unlikely candidate for the limelight. But 25 years ago, the diminutive thale cress ...

More than a structural bystander: Vinculin's unexpected role in cellular mechanical memory

A team of researchers at the University of Liverpool, working in collaboration with the Mechanobiology Institute at the ...

Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting

Additionally, the more than 50 abstracts accepted at ASH include new and updated data from Incyte’s MPN, GVHD and hematology ...
The Law Society

Part two: procedures and practice issues

A practical guide to developing a law firm pro bono programme. Through a mixture of commentary, advice, precedents and background information, the manual provides practical help and advice for law ...